Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03680508

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Advanced Adult Primary Liver Cancer Clinical Trial

Official title:
Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma

Clinical Trial Summary

TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer. This phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) work in combination in treating patients with locally advanced or metastatic liver cancer.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess the objective response rate (ORR) as determined by RECIST v1.1 of advanced hepatocellular cancer (HCC) patients treated with TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody). SECONDARY OBJECTIVES: I. To determine the ORR as determined by the immune related Response Criteria (irRC), duration of response (DOR), time to progression (TTP), progression free survival (PFS), overall survival (OS), and alpha-fetoprotein (AFP) response of study participants. II. To evaluate the safety profile of treated patients. OUTLINE: Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 9 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03680508
Study type Interventional
Source University of Hawaii
Contact Jared D Acoba, MD
Phone 8085318521
Email jacoba@hawaii.edu
Status Recruiting
Phase Phase 2
Start date December 19, 2019
Completion date October 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00787787 - Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer Phase 2
Completed NCT00052364 - Oxaliplatin in Treating Patients With Liver Cancer Phase 2
Completed NCT01229111 - Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Phase 2
Completed NCT00107536 - Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Phase 2
Completed NCT02072356 - Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Early Phase 1
Completed NCT00604721 - Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 2
Completed NCT00101036 - Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT01766219 - CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Terminated NCT00427973 - AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer Phase 2
Completed NCT00321594 - Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Completed NCT00006016 - Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Phase 2
Completed NCT01643499 - Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Phase 1
Completed NCT00639509 - IMC-A12 in Treating Patients With Advanced Liver Cancer Phase 2
Completed NCT00083226 - Doxorubicin and Bortezomib in Treating Patients With Liver Cancer Phase 2
Completed NCT00033462 - Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Phase 2
Completed NCT01666756 - Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Phase 1
Active, not recruiting NCT02119065 - Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
Recruiting NCT02557503 - Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Phase 4